RxDoctor Payments Data

Spencer Pinion, MD

Family Medicine · Covington, LANPI 1326346164

Payments from drug & device makers

$7,533in general payments, 2019–2025

Across 449 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$752
  • Lilly USA, LLC$671
  • Amgen$478
  • Takeda Pharmaceuticals U.S.A., Inc.$264
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,508100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,533 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$80,821
Medicare patients
160
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$71,885
MounjaroTirzepatide50$50,864
JardianceEmpagliflozin41$28,465
JanuviaSitagliptin Phosphate23$23,537
EliquisApixaban16$18,681
TrulicityDulaglutide15$15,715
Synjardy XrEmpagliflozin/Metformin Hcl15$14,827
Repatha SureclickEvolocumab17$13,353
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,242
FarxigaDapagliflozin Propanediol15$11,079
XareltoRivaroxaban15$10,453
Tresiba Flextouch U-200Insulin Degludec12$7,022
BelsomraSuvorexant16$6,681
Liothyronine Sodium74$3,646
SynthroidLevothyroxine Sodium42$3,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,155$71,88574 claims
Lilly USA, LLCMounjaro, Trulicity$671$66,57965 claims
Boehringer IngelheimJardiance, Synjardy Xr$133$43,29356 claims
PfizerEliquis$752$18,68116 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$17$13,57929 claims
AstraZenecaFarxiga$144$11,07915 claims
Johnson & JohnsonXarelto$20$10,45315 claims
AbbVieSynthroid, Armour Thyroid$1,206$6,570109 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$49$2,059252 claims
Acella Pharmaceuticals, LLCNp Thyroid$38$1,21946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →